Analysis of retreatment with monoclonal antibodies in chronic/episodic migraine: Real world data

CONCLUSION: Interruption of treatment with erenumab/fremanezumab for chronic/episodic migraine produces a clinical worsening of the disease requiring retreatment in most cases, approximately after 4 months. Two out of three patients respond positively after restarting monoclonal therapy. This response does not appear to be related to the type of migraine, the specific monoclonal antibody prescribed, or the time to retreatment.PMID:38461112 | DOI:10.1016/j.farma.2024.02.003

Source: Farmacia Hospitalaria - March 9, 2024 Category: Drugs & Pharmacology Authors: Patricia Garc ía-Lloret Mercedes Galv án-Banqueri Mar ía de Las Aguas Robustillo-Cortés Mar ía Fernández-Recio Source Type: research